2025 International Congress » MSA, PSP, CBS: Clinical Trials

Meeting: 2025 International Congress

A Randomized, Double-blind Phase 3 Trial of Amlenetug Versus Placebo in Patients with MSA: The MASCOT Trial

L. Kjærsgaard, M. Nørbæk Jørgensen, S. Zanigni, J. Wiedemann, J. Luthman (Valby, Denmark)

ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy

D. Stamler, C. Wong, P. Trujillo, M. Bradbury, C. Lucas, K. Kmiecik, D. Claassen (Newark, USA)

Brain Target Engagement and Pharmacokinetic-Enzyme Occupancy (PK-EO) Relationship of FNP-223: A Novel Oral OGA Inhibitor for Progressive Supranuclear Palsy – Phase 1 PET Study

R. Pokorny, J M. Ryan, E. Rabiner, G. Searle, C. Varona, M. Schneider, C. Wiessner, J F. Stallaert, B. Permanne, A. Quattropani, D. Beher (Lausanne, Switzerland)

Incorporating Patient and Care Partner Feedback on the Protocol for a Clinical Trial Assessing Progression in MSA

B. Yang, A. Souza Santana, R. Murphy, C. O’Donnell, M. Jørgensen, L. Kjærsgaard, S. Zanigni (Valby, Denmark)

Integrated Management of atypical Parkinsonism: A home-based patient-Centered healthcare model using Telenursing. Baseline data from the Multicentre IMPACT study

R. Cilia, V. Leta, F. Colucci, A. Suppa, F. Valentino, C. Terranova, C. Leuzzi, J. Cordasco, R. Telese, A. Braccia, G. Gaudiano, A. Elia, A. Zampogna, G. Pinola, M. Patera, G. Belluscio, S. Crivellari, E. Antoniazzi, S. Cascino, A. Giaco, A. Masaracchio, C. Moreschi, M. Catotti, R. Eleopra (Messina, Italy)

Intrathecal Administration of Human Oral Mucosa Neural Crest Stem Cells in Moderate/Advanced Multiple System Atrophy: Report on Ongoing Phase 1 Study

T. Gurevich, V. Livneh, O. Aizenstein, M. Artzi, A. Ezra, H. Shabtai, H. Rachima, A. Shuster, B. Koren, H. Goltsman, S. Pitaru (Tel Aviv, Israel)

Neurogenic bladder and affective disorders in parkinsonism

E. Korshunova, M. Khommyatov, M. Samushiya, N. Suponeva (Moscow, Russian Federation)

Neurologic Music Therapy and Non-Invasive Brain Stimulation for Upper Extremity Performance in Patients with Corticobasal Syndrome

K. Kang, I. Sterner, S. Bakhshi, C. Bedell, A. Pantelyat (Baltimore, USA)

Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS)

R. Durcan, H. Paula, D. Street, A. Murley, S. Jones, A. Church, C. Kobylecki, V. Marshall, C. Antoniades, B. Ghosh, J. Rowe (Cambridge, United Kingdom)

Safety, Tolerability and Pharmacokinetics of a Novel Oral OGA Inhibitor (FNP-223) First-in-Human Phase 1 Study

R. Pokorny, J M. Ryan, K. Abd-Elaziz, C. Varona, M. Schneider, C. Wiessner, J F. Stallaert, B. Permanne, A. Quattropani, D. Beher (Lausanne, Switzerland)

The effectiveness and safety of autologous adipose derived stromal vascular components (SVF) in the treatment of multiple system atrophy

ZL. Cai, RX. Li, JW. Li (Suzhou, China)

The IMPACT study: protocol of a randomised controlled single-blind trial evaluating efficacy and cost-effectiveness of telenursing in atypical parkinsonism

R. Cilia, V. Leta, F. Colucci, A. Suppa, F. Valentino, C. Terranova, C. Leuzzi, J. Cordasco, G. Fusi, S. Floridia, F. de Giorgi, R. Telese, A. Braccia, A. Zampogna, G. Pinola, M. Patera, G. Belluscio, S. Crivellari, E. Antoniazzi, S. Cascino, A. Giaco, A. Masaracchio, G. Moreschi, M. Catotti, R. Eleopra (Milan, Italy)

Utilizing the 15-item modification of the PSPRS rating scale (mPSPRS-15) as the primary endpoint for future clinical trials in progressive supranuclear palsy

F. Nery, T. Nevmyrych, J. Murphy, S. Wu, Y. Zabar, A. Gafson, S. Bullain, J. O’Gorman (Cambridge, USA)

« View all sessions from the 2025 International Congress.